Dacomitinib/Dacomitinib price and comparison in different regions

Dacomitinib/Dacomitinib (Dacomitinib) is a second-generation irreversible EGFR-TKI, suitable for first-line treatment of EGFR mutation-positive non-small cell lung cancer patients. Its irreversible binding effect results in long-term inhibition of EGFR signaling, thereby delaying tumor cell proliferation and prolonging progression-free survival. Compared with earlier generation drugs, dacomitinib has shown lower disease recurrence rates and more stable efficacy in some clinical trials.

In the domestic market, the original drug dacomitinib has been launched and included in the Category B medical insurance catalog. The common specifications are15mg 30 tablets per box, and the price is about more than 1,000 yuan. This price combined with medical insurance reimbursement makes it financially accessible to patients. In overseas markets, the European version of the original dacomitinib drug is 45 mg and 30 tablets per box, and the price may exceed RMB 20,000, which may fluctuate due to exchange rates and regional pricing policies. There is also a supply of generic drugs in overseas markets. For example, the generic version of dacomitinib produced by Laos Lucius Pharmaceutical Factory and Element Pharmaceutical Factory has the same specifications of 45mg*30 tablets per box and the price is about 800 yuan. Its ingredients are consistent with the original drug, providing a more economical choice.

Dacomitinib is flexible in use and is mainly taken orally once a day, making it easier for patients to take the medication at home for a long time. The application of the drug is not only limited to domestic patients, but also provides feasible treatment options for patients with EGFR mutated non-small cell lung cancer in different regions around the world. High overseas prices are mainly related to research and development costs, market policies and medical insurance coverage, while the emergence of generic drugs has further improved patient accessibility.

Overall, dacomitinib has stable clinical application and clear indications worldwide, while price differences are mainly affected by regional economic levels, medical insurance policies and drug patent status. Domestic patients can obtain more economical drugs with the support of medical insurance, while overseas patients may choose original drugs or quality-controlled generic drugs.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro